COVID-19

CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study

First challenge infection study in preclinical mouse model to provide evidence for protection against SARS-CoV-2 variantCVnCoV induces robust antibody titers...

CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection

Data provided further evidence on immunogenicity and protective efficacy of CVnCoV ∙ Induction of robust antibody and T cell responses...

Pharnext and the University Hospital Institute Méditerranée Infection Announce a Joint Effort to Evaluate Repurposed Drugs for Potential Use Against the COVID-19 Virus

Rapid in vitro testing of repurposed drug candidates identified by Pharnext's PLEOTHERAPYTM Artificial Intelligence platformPARIS, France, 8:00am, April 22, 2020 (CET) - Pharnext SA...

error: Content is protected !!